Profile

Cover photo
Amarantus BioScience Holdings, Inc.
39 followers|22,280 views
AboutPosts

Stream

 
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
SAN FRANCISCO, February 5, 2016 /PRNewswire/ --. Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the ...
1
Add a comment...
 
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease http://bit.ly/1nCJyGo
SAN FRANCISCO, January 29, 2016 /PRNewswire/ --. Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the issuance of Chinese patent number ZL2009801163060 entitled ...
1
 
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
SAN FRANCISCO and SCOTTSDALE, Arizona, January 19, 2016 /PRNewswire/ --. Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, and Avant Diagnostics (OTCQB: AVDX), a medical diagnostic technology ...
1
Add a comment...
 
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
SAN FRANCISCO, January 11, 2016 /PRNewswire/ --. Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan diseases, today announced that President & CEO Gerald E. Commissiong will be presenting at 2pm PT at the First ...
1
Add a comment...
 
Amarantus BioScience Holdings, Inc., today provided an update on the status of its current manufacturing process validation for producing ESS at Lonza Walkersville. Ongoing engineering run activities are progressing successfully, and Amarantus expects to complete the necessary steps to confirm the process in January. Upon completing the validation studies, Amarantus will be ready from the operational perspective to open the planned Phase 2 clinical study for the treatment of full thickness thermal burns covering over 50% of the body. The trial is being conducted under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army at the Institute for Surgical Research at Fort Sam Houston in Texas. Read the full press release for additional details and information: http://bit.ly/1YyOR4G
SAN FRANCISCO, Dec. 22, 2015 /PRNewswire/ -- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today provided an update on the status of its current manufacturing process validation ...
1
Add a comment...
 
Click here to view Amarantus CEO Gerald Commissiong's interview with Small Cap Nation's Jane King: http://bit.ly/1Qv84EX
1
Add a comment...
Have them in circles
39 people
Ana Nassaney's profile photo
Steven Angel's profile photo
One Mind's profile photo
Ankit Goswami's profile photo
Christopher Scott's profile photo
sludge reports's profile photo
Mahesh T.N's profile photo
Struggling To Focus's profile photo
Rachel Francine's profile photo
 
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
SAN FRANCISCO, February 3, 2016 /PRNewswire/ --. Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that its wholly-owned subsidiary Cutanogen Corporation has received ...
1
Add a comment...
 
Amarantus Announces $1M Investment
SAN FRANCISCO, January 27, 2016 /PRNewswire/ --. Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $1M investment from an investor introduced to the Company by ...
1
Add a comment...
 
Amarantus to Present at ICV Sonoma Event http://bit.ly/1n5o84m
SAN FRANCISCO, January 15, 2016 /PRNewswire/ --. Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan disease, today announced the Company will be presenting at the ICV Sonoma event. The conference is being held ...
1
 
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
SAN FRANCISCO, December 29, 2015 /PRNewswire/ --. Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) and ...
1
Add a comment...
 
In an interview with Jane King of Small Cap Nation, Gerald Commissiong discusses why Amarantus has established itself as a holding company. Watch here: http://bit.ly/1Qv84EX
1
Add a comment...
 
Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID http://bit.ly/1YkyOY0
SAN FRANCISCO, December 16, 2015 /PRNewswire/ --. Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced the publication of a new independent peer-reviewed publication ...
1
Add a comment...
People
Have them in circles
39 people
Ana Nassaney's profile photo
Steven Angel's profile photo
One Mind's profile photo
Ankit Goswami's profile photo
Christopher Scott's profile photo
sludge reports's profile photo
Mahesh T.N's profile photo
Struggling To Focus's profile photo
Rachel Francine's profile photo
Contact Information
Contact info
Phone
(408) 737-2734
Email
Address
c/o Janssen Labs @ QB3 953 Indiana Street San Francisco, CA 94107
c/o ICS Corporate Services SA 29 quai du Mont Blanc CH-1201 Geneva Switzerland
Story
Tagline
Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology, regenerative medicine and orphan diseases.
Introduction

Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. More recently, AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery.

Amarantus is a Founding Member of Global Brain Health Coalition (GBHC). The GBHC mission is to become the leading global voice for brain health awareness and empowerment by converging science, clinical research and impact.